human cd8 t cells Search Results


97
Miltenyi Biotec human cd8 t cell isolation kit
Human Cd8 T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/CD8%2B+T+Cell+Isolation+Kit%2C+human/10__1080_slash_2162402x__2018__1509821-212-40-46
Average 97 stars, based on 1 article reviews
human cd8 t cell isolation kit - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

93
Miltenyi Biotec macsxpress whole blood cd8 t cell isolation kit
Macsxpress Whole Blood Cd8 T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/MACSxpress+Whole+Blood+CD8+T+Cell+Isolation+Kit%2C+human/pm35019724-244-17-25
Average 93 stars, based on 1 article reviews
macsxpress whole blood cd8 t cell isolation kit - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
MedChemExpress immunomagnetic separation kit
Immunomagnetic Separation Kit, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pmc13458028-145-14-25
Average 94 stars, based on 1 article reviews
immunomagnetic separation kit - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

95
Miltenyi Biotec naïve cd8 t cell isolation kit
Naïve Cd8 T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/Naive+CD8%2B+T+Cell+Isolation+Kit%2C+human/pmc10709131-103-0-8
Average 95 stars, based on 1 article reviews
naïve cd8 t cell isolation kit - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

94
R&D Systems magcellect human cd8 t cell isolation kit
Magcellect Human Cd8 T Cell Isolation Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/MagCellect+Human+CD8%2B+T+Cell+Isolation+Kit/pm40665335-98-19-26
Average 94 stars, based on 1 article reviews
magcellect human cd8 t cell isolation kit - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec non human primate cd8 t cell isolation kit
Phenotypic and functional characteristics pre- and post CTL infusion. a Functional profiles of <t>CD8</t> + T-cells pre- and post- CTL were evaluated by peptide antigen-specific responses and shown as the frequencies of Env-specific CD8 + T-cells producing CD107a, IFN-γ, MIP-1β and TNF-α ( p < 0.0001 using Wilcoxon signed-rank test, n = 6). b Activation profile of Env-specific, IFN-γ-producing CD8 + T-cells for both pre- and post-infusion responses, based on surface expression of CD69, HLADR, CCR5 and intracellular expression of Ki67 (* p < 0.05 and ** p < 0.01 using unpaired Students t test, Mean ± s.d. are presented in all graphs, n = 6). c Env-peptide functional profiles of CD8 + T-cells in controllers, non-controllers and untreated animals ( p < 0.0001 using Wilcoxon signed-rank test, n = 8). d Env-specific, IFN-γ + CD3 + CD8 + central memory T cells pre-and post-CTL infusion among controllers, non-controllers and untreated animals ( p = 0.038 using paired Students t-test, n = 8). e PD-1 + Ki67 + expression on Env-specific CD8 + T-cells pre- and post-CTL infusion among controllers, non-controllers and untreated animals ( p = 0.01 using paired Students t-test, n = 8). f Env-specific CD8 + T-cells expressing PD-1 + Ki67 + were positively correlated with viral load post infusion (Spearman’s correlation coefficient (R) and P values are indicated. Note that x-axis is log 10 scales, n = 8). g The SHIV-suppressive activity of circulating CD8 + T-cells from controllers and non-controllers were measured on autologous activated CD4 + T-cells infected with SHIV-162P3. SHIV suppression was reported as the Log inhibition in p27 titers in CD4 + T-cells supernatants when autologous ex vivo Env-stimulated CD8 + T-cells were added at a 1:1 ratio to the culture ( p = 0.0001 using unpaired Students t test, Mean ± s.d. is presented, n = 6). h Relationship between SHIV-suppressive activity (% inhibition) of circulating CD8 + T-cells and set point of viral load (Spearman’s correlation coefficient (R) and P values are indicated. Note that x- and y-axis are log 10 scales, n = 6)
Non Human Primate Cd8 T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/CD8%2B+T+Cell+Isolation+Kit%2C+non-human+primate/pmc06529452-147-15-22
Average 96 stars, based on 1 article reviews
non human primate cd8 t cell isolation kit - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

97
Miltenyi Biotec rapid cytokine inspector
Emerging T-cell-based adoptive immunotherapy strategies to treat COVID-19 infection. Main methods: A direct selection with IFNγ CCS CliniMACS® Prodigy device. B Direct selection with CliniMACS® Plus device. C Ex vivo T-cell expansion. D Ex vivo cell expansion and CRISPR gene-modified T-cells. E T-cell receptor-engineered <t>CD8</t> + T-cell. F Treg/Th2 hybrid T-cells. Abbreviations: PBMC, peripheral blood mononuclear cell; <t>IFNγ,</t> <t>interferon-γ;</t> HLA, human leukocyte antigen; Th, T helper cell; T-reg, T-regulatory cell; NCT, National Clinical Trial; DPC-OHII, Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases; CCS, <t>cytokine</t> capture system; MoAb, monoclonal antibody; ETT-TUKEB, Research Ethics Committee of the Hungarian National Medical Scientific Council; HSCT, hematopoietic stem cell transplantation; IL, interleukin; SOT, solid organ transplantation; CRISPR, RNA-controlled clustered regularly interspaced short palindromic repeats; Cas-9, caspase-9; NR3C1, nuclear receptor subfamily 3 group C member 1; PD1, programmed cell death protein1; ACE2, angiotensin-converting enzyme 2; FKBP12, FK506 binding protein 1A, 12 kDa; KO, knockout; TReAT, Tacrolimus-resistant antiviral T-cell therapy; ARDS, acute respiratory distress syndrome; TCR, T-cell receptor; NA, not available
Rapid Cytokine Inspector, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/Rapid+Cytokine+Inspector+(CD4%2FCD8+T+Cell)+Kit%2C+human/pmc10828167-63-7-15
Average 97 stars, based on 1 article reviews
rapid cytokine inspector - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

93
R&D Systems magcellect human cd81 t cell isolation kit
Emerging T-cell-based adoptive immunotherapy strategies to treat COVID-19 infection. Main methods: A direct selection with IFNγ CCS CliniMACS® Prodigy device. B Direct selection with CliniMACS® Plus device. C Ex vivo T-cell expansion. D Ex vivo cell expansion and CRISPR gene-modified T-cells. E T-cell receptor-engineered <t>CD8</t> + T-cell. F Treg/Th2 hybrid T-cells. Abbreviations: PBMC, peripheral blood mononuclear cell; <t>IFNγ,</t> <t>interferon-γ;</t> HLA, human leukocyte antigen; Th, T helper cell; T-reg, T-regulatory cell; NCT, National Clinical Trial; DPC-OHII, Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases; CCS, <t>cytokine</t> capture system; MoAb, monoclonal antibody; ETT-TUKEB, Research Ethics Committee of the Hungarian National Medical Scientific Council; HSCT, hematopoietic stem cell transplantation; IL, interleukin; SOT, solid organ transplantation; CRISPR, RNA-controlled clustered regularly interspaced short palindromic repeats; Cas-9, caspase-9; NR3C1, nuclear receptor subfamily 3 group C member 1; PD1, programmed cell death protein1; ACE2, angiotensin-converting enzyme 2; FKBP12, FK506 binding protein 1A, 12 kDa; KO, knockout; TReAT, Tacrolimus-resistant antiviral T-cell therapy; ARDS, acute respiratory distress syndrome; TCR, T-cell receptor; NA, not available
Magcellect Human Cd81 T Cell Isolation Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/MagCellect+Human+CD8%2B+T+Cell+Isolation+Kit/pm33903172-102-15-23
Average 93 stars, based on 1 article reviews
magcellect human cd81 t cell isolation kit - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
iQ Biosciences human cd8 t cells
Emerging T-cell-based adoptive immunotherapy strategies to treat COVID-19 infection. Main methods: A direct selection with IFNγ CCS CliniMACS® Prodigy device. B Direct selection with CliniMACS® Plus device. C Ex vivo T-cell expansion. D Ex vivo cell expansion and CRISPR gene-modified T-cells. E T-cell receptor-engineered <t>CD8</t> + T-cell. F Treg/Th2 hybrid T-cells. Abbreviations: PBMC, peripheral blood mononuclear cell; <t>IFNγ,</t> <t>interferon-γ;</t> HLA, human leukocyte antigen; Th, T helper cell; T-reg, T-regulatory cell; NCT, National Clinical Trial; DPC-OHII, Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases; CCS, <t>cytokine</t> capture system; MoAb, monoclonal antibody; ETT-TUKEB, Research Ethics Committee of the Hungarian National Medical Scientific Council; HSCT, hematopoietic stem cell transplantation; IL, interleukin; SOT, solid organ transplantation; CRISPR, RNA-controlled clustered regularly interspaced short palindromic repeats; Cas-9, caspase-9; NR3C1, nuclear receptor subfamily 3 group C member 1; PD1, programmed cell death protein1; ACE2, angiotensin-converting enzyme 2; FKBP12, FK506 binding protein 1A, 12 kDa; KO, knockout; TReAT, Tacrolimus-resistant antiviral T-cell therapy; ARDS, acute respiratory distress syndrome; TCR, T-cell receptor; NA, not available
Human Cd8 T Cells, supplied by iQ Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/Purified+Human+CD8+T+Cells/pm38326607-499-0-4
Average 94 stars, based on 1 article reviews
human cd8 t cells - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc human cd8+ t cells
Emerging T-cell-based adoptive immunotherapy strategies to treat COVID-19 infection. Main methods: A direct selection with IFNγ CCS CliniMACS® Prodigy device. B Direct selection with CliniMACS® Plus device. C Ex vivo T-cell expansion. D Ex vivo cell expansion and CRISPR gene-modified T-cells. E T-cell receptor-engineered <t>CD8</t> + T-cell. F Treg/Th2 hybrid T-cells. Abbreviations: PBMC, peripheral blood mononuclear cell; <t>IFNγ,</t> <t>interferon-γ;</t> HLA, human leukocyte antigen; Th, T helper cell; T-reg, T-regulatory cell; NCT, National Clinical Trial; DPC-OHII, Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases; CCS, <t>cytokine</t> capture system; MoAb, monoclonal antibody; ETT-TUKEB, Research Ethics Committee of the Hungarian National Medical Scientific Council; HSCT, hematopoietic stem cell transplantation; IL, interleukin; SOT, solid organ transplantation; CRISPR, RNA-controlled clustered regularly interspaced short palindromic repeats; Cas-9, caspase-9; NR3C1, nuclear receptor subfamily 3 group C member 1; PD1, programmed cell death protein1; ACE2, angiotensin-converting enzyme 2; FKBP12, FK506 binding protein 1A, 12 kDa; KO, knockout; TReAT, Tacrolimus-resistant antiviral T-cell therapy; ARDS, acute respiratory distress syndrome; TCR, T-cell receptor; NA, not available
Human Cd8+ T Cells, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/human+cd8++t+cells/pm38492435-67-2-7
Average 90 stars, based on 1 article reviews
human cd8+ t cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc primary human cd8+ t cells
Emerging T-cell-based adoptive immunotherapy strategies to treat COVID-19 infection. Main methods: A direct selection with IFNγ CCS CliniMACS® Prodigy device. B Direct selection with CliniMACS® Plus device. C Ex vivo T-cell expansion. D Ex vivo cell expansion and CRISPR gene-modified T-cells. E T-cell receptor-engineered <t>CD8</t> + T-cell. F Treg/Th2 hybrid T-cells. Abbreviations: PBMC, peripheral blood mononuclear cell; <t>IFNγ,</t> <t>interferon-γ;</t> HLA, human leukocyte antigen; Th, T helper cell; T-reg, T-regulatory cell; NCT, National Clinical Trial; DPC-OHII, Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases; CCS, <t>cytokine</t> capture system; MoAb, monoclonal antibody; ETT-TUKEB, Research Ethics Committee of the Hungarian National Medical Scientific Council; HSCT, hematopoietic stem cell transplantation; IL, interleukin; SOT, solid organ transplantation; CRISPR, RNA-controlled clustered regularly interspaced short palindromic repeats; Cas-9, caspase-9; NR3C1, nuclear receptor subfamily 3 group C member 1; PD1, programmed cell death protein1; ACE2, angiotensin-converting enzyme 2; FKBP12, FK506 binding protein 1A, 12 kDa; KO, knockout; TReAT, Tacrolimus-resistant antiviral T-cell therapy; ARDS, acute respiratory distress syndrome; TCR, T-cell receptor; NA, not available
Primary Human Cd8+ T Cells, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/human+primary+cd8++t+cells/pm36991534-261-9-14
Average 90 stars, based on 1 article reviews
primary human cd8+ t cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc untouched easyseptm human memory cd8+ t cell enrichment kit
Emerging T-cell-based adoptive immunotherapy strategies to treat COVID-19 infection. Main methods: A direct selection with IFNγ CCS CliniMACS® Prodigy device. B Direct selection with CliniMACS® Plus device. C Ex vivo T-cell expansion. D Ex vivo cell expansion and CRISPR gene-modified T-cells. E T-cell receptor-engineered <t>CD8</t> + T-cell. F Treg/Th2 hybrid T-cells. Abbreviations: PBMC, peripheral blood mononuclear cell; <t>IFNγ,</t> <t>interferon-γ;</t> HLA, human leukocyte antigen; Th, T helper cell; T-reg, T-regulatory cell; NCT, National Clinical Trial; DPC-OHII, Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases; CCS, <t>cytokine</t> capture system; MoAb, monoclonal antibody; ETT-TUKEB, Research Ethics Committee of the Hungarian National Medical Scientific Council; HSCT, hematopoietic stem cell transplantation; IL, interleukin; SOT, solid organ transplantation; CRISPR, RNA-controlled clustered regularly interspaced short palindromic repeats; Cas-9, caspase-9; NR3C1, nuclear receptor subfamily 3 group C member 1; PD1, programmed cell death protein1; ACE2, angiotensin-converting enzyme 2; FKBP12, FK506 binding protein 1A, 12 kDa; KO, knockout; TReAT, Tacrolimus-resistant antiviral T-cell therapy; ARDS, acute respiratory distress syndrome; TCR, T-cell receptor; NA, not available
Untouched Easyseptm Human Memory Cd8+ T Cell Enrichment Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd8+t+cells/untouched+easyseptm+human+memory+cd8++t+cell+enrichment+kit/pm39709477-318-19-24
Average 90 stars, based on 1 article reviews
untouched easyseptm human memory cd8+ t cell enrichment kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Phenotypic and functional characteristics pre- and post CTL infusion. a Functional profiles of CD8 + T-cells pre- and post- CTL were evaluated by peptide antigen-specific responses and shown as the frequencies of Env-specific CD8 + T-cells producing CD107a, IFN-γ, MIP-1β and TNF-α ( p < 0.0001 using Wilcoxon signed-rank test, n = 6). b Activation profile of Env-specific, IFN-γ-producing CD8 + T-cells for both pre- and post-infusion responses, based on surface expression of CD69, HLADR, CCR5 and intracellular expression of Ki67 (* p < 0.05 and ** p < 0.01 using unpaired Students t test, Mean ± s.d. are presented in all graphs, n = 6). c Env-peptide functional profiles of CD8 + T-cells in controllers, non-controllers and untreated animals ( p < 0.0001 using Wilcoxon signed-rank test, n = 8). d Env-specific, IFN-γ + CD3 + CD8 + central memory T cells pre-and post-CTL infusion among controllers, non-controllers and untreated animals ( p = 0.038 using paired Students t-test, n = 8). e PD-1 + Ki67 + expression on Env-specific CD8 + T-cells pre- and post-CTL infusion among controllers, non-controllers and untreated animals ( p = 0.01 using paired Students t-test, n = 8). f Env-specific CD8 + T-cells expressing PD-1 + Ki67 + were positively correlated with viral load post infusion (Spearman’s correlation coefficient (R) and P values are indicated. Note that x-axis is log 10 scales, n = 8). g The SHIV-suppressive activity of circulating CD8 + T-cells from controllers and non-controllers were measured on autologous activated CD4 + T-cells infected with SHIV-162P3. SHIV suppression was reported as the Log inhibition in p27 titers in CD4 + T-cells supernatants when autologous ex vivo Env-stimulated CD8 + T-cells were added at a 1:1 ratio to the culture ( p = 0.0001 using unpaired Students t test, Mean ± s.d. is presented, n = 6). h Relationship between SHIV-suppressive activity (% inhibition) of circulating CD8 + T-cells and set point of viral load (Spearman’s correlation coefficient (R) and P values are indicated. Note that x- and y-axis are log 10 scales, n = 6)

Journal: Nature Communications

Article Title: CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques

doi: 10.1038/s41467-019-09725-6

Figure Lengend Snippet: Phenotypic and functional characteristics pre- and post CTL infusion. a Functional profiles of CD8 + T-cells pre- and post- CTL were evaluated by peptide antigen-specific responses and shown as the frequencies of Env-specific CD8 + T-cells producing CD107a, IFN-γ, MIP-1β and TNF-α ( p < 0.0001 using Wilcoxon signed-rank test, n = 6). b Activation profile of Env-specific, IFN-γ-producing CD8 + T-cells for both pre- and post-infusion responses, based on surface expression of CD69, HLADR, CCR5 and intracellular expression of Ki67 (* p < 0.05 and ** p < 0.01 using unpaired Students t test, Mean ± s.d. are presented in all graphs, n = 6). c Env-peptide functional profiles of CD8 + T-cells in controllers, non-controllers and untreated animals ( p < 0.0001 using Wilcoxon signed-rank test, n = 8). d Env-specific, IFN-γ + CD3 + CD8 + central memory T cells pre-and post-CTL infusion among controllers, non-controllers and untreated animals ( p = 0.038 using paired Students t-test, n = 8). e PD-1 + Ki67 + expression on Env-specific CD8 + T-cells pre- and post-CTL infusion among controllers, non-controllers and untreated animals ( p = 0.01 using paired Students t-test, n = 8). f Env-specific CD8 + T-cells expressing PD-1 + Ki67 + were positively correlated with viral load post infusion (Spearman’s correlation coefficient (R) and P values are indicated. Note that x-axis is log 10 scales, n = 8). g The SHIV-suppressive activity of circulating CD8 + T-cells from controllers and non-controllers were measured on autologous activated CD4 + T-cells infected with SHIV-162P3. SHIV suppression was reported as the Log inhibition in p27 titers in CD4 + T-cells supernatants when autologous ex vivo Env-stimulated CD8 + T-cells were added at a 1:1 ratio to the culture ( p = 0.0001 using unpaired Students t test, Mean ± s.d. is presented, n = 6). h Relationship between SHIV-suppressive activity (% inhibition) of circulating CD8 + T-cells and set point of viral load (Spearman’s correlation coefficient (R) and P values are indicated. Note that x- and y-axis are log 10 scales, n = 6)

Article Snippet: Following two rounds of peptide stimulation, the Env-specific CD8 + T cells were isolated by non-human primate CD8 + T-cell isolation kit (Miltenyi Biotec, Catalogue# 130-092-143) and expanded using the Rapid Expansion Protocol in a sterile 25-cm 2 tissue culture flasks.

Techniques: Functional Assay, Activation Assay, Expressing, Activity Assay, Infection, Inhibition, Ex Vivo

Phenotypic and functional characterization of CTL-lines. a In vitro specific antigen recognition of CTL-lines. Data is shown as Grand median for each group. Each symbol represented one animal ( n = 6). b P27 titers in the culture supernatants of PHA-activated CD4 + T-cells infected in vitro with replicative SHIV-SF162P3, in the absence (CD4 alone) or presence of autologous CTL Lines (1:1, 2:1 and 5:1 of ET ratio). Each symbol represented one animal ( n = 6). c The capacity of CTL-lines to suppress SHIV replication in autologous CD4 + T-cells. The Log of p27 decreased when CD4 + T-cells were cocultured with CTL-lines. Each symbol represented one animal ( n = 6). d Correlation between cytotoxic capacity (% inhibition) and frequencies of Env-specific IFN- γ producing (Spearman’s correlation coefficient (R) and P values are indicated. Note that y-axis is log 10 scales, n = 6). e Memory phenotypic characterization of CTL-lines. Data is shown as Grand median for each group. Each symbol represented one animal ( n = 6). f Relationship between PBMCs Env-specific, IFN-γ + CD3 + CD8 + central memory T cells post-infusion and Env-specific memory response of CTL-lines (Spearman’s correlation coefficient (R) and P values are indicated, n = 6)

Journal: Nature Communications

Article Title: CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques

doi: 10.1038/s41467-019-09725-6

Figure Lengend Snippet: Phenotypic and functional characterization of CTL-lines. a In vitro specific antigen recognition of CTL-lines. Data is shown as Grand median for each group. Each symbol represented one animal ( n = 6). b P27 titers in the culture supernatants of PHA-activated CD4 + T-cells infected in vitro with replicative SHIV-SF162P3, in the absence (CD4 alone) or presence of autologous CTL Lines (1:1, 2:1 and 5:1 of ET ratio). Each symbol represented one animal ( n = 6). c The capacity of CTL-lines to suppress SHIV replication in autologous CD4 + T-cells. The Log of p27 decreased when CD4 + T-cells were cocultured with CTL-lines. Each symbol represented one animal ( n = 6). d Correlation between cytotoxic capacity (% inhibition) and frequencies of Env-specific IFN- γ producing (Spearman’s correlation coefficient (R) and P values are indicated. Note that y-axis is log 10 scales, n = 6). e Memory phenotypic characterization of CTL-lines. Data is shown as Grand median for each group. Each symbol represented one animal ( n = 6). f Relationship between PBMCs Env-specific, IFN-γ + CD3 + CD8 + central memory T cells post-infusion and Env-specific memory response of CTL-lines (Spearman’s correlation coefficient (R) and P values are indicated, n = 6)

Article Snippet: Following two rounds of peptide stimulation, the Env-specific CD8 + T cells were isolated by non-human primate CD8 + T-cell isolation kit (Miltenyi Biotec, Catalogue# 130-092-143) and expanded using the Rapid Expansion Protocol in a sterile 25-cm 2 tissue culture flasks.

Techniques: Functional Assay, In Vitro, Infection, Inhibition

Kinetics of Env-specific immune response and the correlates of virologic control. a The frequency of circulating antigen-specific CD8 + T-cells in PBMCs was measured at the indicated time points from SHIV controllers (Animals 1–3, n = 3), non-controllers (Animals 4–6, n = 3) and untreated animals (Animals 7 and 8, n = 2). y -axis, from Lift to Right, frequency of HIV CN54 Env-specific CD8 + T-cell producing IFN-γ + and frequency of SIV mac239 Gag-specific CD8 + T-cell producing IFN-γ + . wk, weeks. b Correlations between Env-specific CD8 + T-cell responses at 2 weeks after CTL infusion and set point log SHIV RNA after CTL infusion (Spearman’s correlation coefficient (R) and P values are indicated. Note that x-axis is log 10 scales, n = 8). c Depletion of CD8 + T cells in controller macaques results in the rapid induction of plasma viremia. CD8 + T-cell count and plasma viral load were shown in SHIV controller macaques following CD8 depletion (Animal 1 and 3, n = 2). x-axis, days post- ART interruption. The shaded gray indicated time points post-CD8 depletion

Journal: Nature Communications

Article Title: CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques

doi: 10.1038/s41467-019-09725-6

Figure Lengend Snippet: Kinetics of Env-specific immune response and the correlates of virologic control. a The frequency of circulating antigen-specific CD8 + T-cells in PBMCs was measured at the indicated time points from SHIV controllers (Animals 1–3, n = 3), non-controllers (Animals 4–6, n = 3) and untreated animals (Animals 7 and 8, n = 2). y -axis, from Lift to Right, frequency of HIV CN54 Env-specific CD8 + T-cell producing IFN-γ + and frequency of SIV mac239 Gag-specific CD8 + T-cell producing IFN-γ + . wk, weeks. b Correlations between Env-specific CD8 + T-cell responses at 2 weeks after CTL infusion and set point log SHIV RNA after CTL infusion (Spearman’s correlation coefficient (R) and P values are indicated. Note that x-axis is log 10 scales, n = 8). c Depletion of CD8 + T cells in controller macaques results in the rapid induction of plasma viremia. CD8 + T-cell count and plasma viral load were shown in SHIV controller macaques following CD8 depletion (Animal 1 and 3, n = 2). x-axis, days post- ART interruption. The shaded gray indicated time points post-CD8 depletion

Article Snippet: Following two rounds of peptide stimulation, the Env-specific CD8 + T cells were isolated by non-human primate CD8 + T-cell isolation kit (Miltenyi Biotec, Catalogue# 130-092-143) and expanded using the Rapid Expansion Protocol in a sterile 25-cm 2 tissue culture flasks.

Techniques: Control, Clinical Proteomics, Cell Counting

Emerging T-cell-based adoptive immunotherapy strategies to treat COVID-19 infection. Main methods: A direct selection with IFNγ CCS CliniMACS® Prodigy device. B Direct selection with CliniMACS® Plus device. C Ex vivo T-cell expansion. D Ex vivo cell expansion and CRISPR gene-modified T-cells. E T-cell receptor-engineered CD8 + T-cell. F Treg/Th2 hybrid T-cells. Abbreviations: PBMC, peripheral blood mononuclear cell; IFNγ, interferon-γ; HLA, human leukocyte antigen; Th, T helper cell; T-reg, T-regulatory cell; NCT, National Clinical Trial; DPC-OHII, Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases; CCS, cytokine capture system; MoAb, monoclonal antibody; ETT-TUKEB, Research Ethics Committee of the Hungarian National Medical Scientific Council; HSCT, hematopoietic stem cell transplantation; IL, interleukin; SOT, solid organ transplantation; CRISPR, RNA-controlled clustered regularly interspaced short palindromic repeats; Cas-9, caspase-9; NR3C1, nuclear receptor subfamily 3 group C member 1; PD1, programmed cell death protein1; ACE2, angiotensin-converting enzyme 2; FKBP12, FK506 binding protein 1A, 12 kDa; KO, knockout; TReAT, Tacrolimus-resistant antiviral T-cell therapy; ARDS, acute respiratory distress syndrome; TCR, T-cell receptor; NA, not available

Journal: GeroScience

Article Title: Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review

doi: 10.1007/s11357-023-00858-7

Figure Lengend Snippet: Emerging T-cell-based adoptive immunotherapy strategies to treat COVID-19 infection. Main methods: A direct selection with IFNγ CCS CliniMACS® Prodigy device. B Direct selection with CliniMACS® Plus device. C Ex vivo T-cell expansion. D Ex vivo cell expansion and CRISPR gene-modified T-cells. E T-cell receptor-engineered CD8 + T-cell. F Treg/Th2 hybrid T-cells. Abbreviations: PBMC, peripheral blood mononuclear cell; IFNγ, interferon-γ; HLA, human leukocyte antigen; Th, T helper cell; T-reg, T-regulatory cell; NCT, National Clinical Trial; DPC-OHII, Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases; CCS, cytokine capture system; MoAb, monoclonal antibody; ETT-TUKEB, Research Ethics Committee of the Hungarian National Medical Scientific Council; HSCT, hematopoietic stem cell transplantation; IL, interleukin; SOT, solid organ transplantation; CRISPR, RNA-controlled clustered regularly interspaced short palindromic repeats; Cas-9, caspase-9; NR3C1, nuclear receptor subfamily 3 group C member 1; PD1, programmed cell death protein1; ACE2, angiotensin-converting enzyme 2; FKBP12, FK506 binding protein 1A, 12 kDa; KO, knockout; TReAT, Tacrolimus-resistant antiviral T-cell therapy; ARDS, acute respiratory distress syndrome; TCR, T-cell receptor; NA, not available

Article Snippet: For the detection of the IFN-γ, the Rapid Cytokine Inspector (CD4-CD8 T-cell) Kit (ref: 130-097-343, Miltenyi Biotec, Bergisch Gladbach, Germany), supplemented with anti-cytokine antibody RCI Anti-IFN-c-PE (ref: 130-097-600, Miltenyi Biotec Bergisch Gladbach, Germany) was used.

Techniques: Infection, Selection, Ex Vivo, CRISPR, Modification, Transplantation Assay, Binding Assay, Knock-Out